Background: We have performed this study to evaluate the association between H19 rs217727 polymorphism and the risk of cancer.
Methods: An odds ratio (OR) with a 95% confidence interval (CI) was applied to determine a potential association.
Results: A total of 17 case-control publications were selected. This meta-analysis showed that H19 rs217727 has a significant increased association with cancer risk in allelic, homozygous, heterozygote, dominant and recessive models (T vs C: OR = 1.16, 95% CI = 1.06-1.27, I2 = 75.7; TT vs CC: OR = 1.29, 95% CI = 1.06-1.56, I2 = 71.6; CT vs CC: OR = 1.15, 95% CI = 1.01-1.31, I2 = 75.4; CT + TT vs CC: OR = 1.20, 95% CI = 1.05-1.36, I2 = 76.5; TT vs CT + CC: OR = 1.22, 95% CI = 1.02-1.45, I2 = 70.6;). In the subgroup analysis of smoking status, both smokers and nonsmokers showed an increase in cancer risk in allelic, homozygous, dominant and heterozygote models.
Conclusion: This meta-analysis revealed H19 rs217727 may influence cancer susceptibility.
Keywords: Cancer risk; H19; Meta-analysis; Polymorphism; rs217727.